Preventing Breast Cancer Recurrence--anastrozole May Be More Effective

Recently, the ongoing United States Clinical Oncology annual meeting, researchers from Loyola University of Chicago academic reports, they reported that they found is less than 60 years of age in postmenopausal patients with ductal carcinoma in situ in a mastectomy and radiation therapy, taking anastrozole than those who took tamoxifen in the prevention of recurrence of breast cancer more effectively. Ductal carcinoma in situ is a non-invasive early stage breast cancer can be cured, the cancer cells now infiltration of small ducts of the breast without the surrounding stroma. One researcher noted that this study for patients with this type of non-invasive breast cancer and a mastectomy and radiation therapy in postmenopausal women with a new option, but also can help physicians and patients make more rational treatment decisions to help prevent breast cancer recurrence. In the phase III clinical study, researchers with ductal carcinoma in situ and a mastectomy and radiation therapy in postmenopausal women were randomly divided into two groups, one group of 20mg tamoxifen daily, while another group of 1mg a day anastrozole, researchers tracked them. Results showed that in the observation of 10, 93.5% women who took anastrozole without invasive or non-invasive breast cancer recurrence, compared to 89.2% in women taking tamoxifen without invasive or non-invasive breast cancer recurrence.